Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

NCT ID: NCT00346983

Last Updated: 2008-05-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-06-30
• Study Completion Date: 2007-05-31

Brief Summary

This research is being conducted to look at the effects of an intraocular drug (pegaptanib, also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that often occurs following cataract surgery in patients with diabetic eye disease. Swelling in the retina can lead to blurry vision, and Macugen may reduce this swelling. Eyedrops that decrease inflammation also may help to stop some of the swelling. We are testing this drug (pegaptanib) to see if it can decrease swelling in the retina and improve vision in patients with diabetes who are having cataract surgery.

Detailed Description

Macular edema occurs as a complication of cataract surgery in approximately 2% of all surgeries. In this condition, cystic, fluid-filled spaces develop in the outer plexiform layer of the retina resulting in a loss of vision. This condition is termed "Cystoid Macular Edema (CME)." In non-diabetics, the majority of such cases resolve spontaneously.

Diabetic macular edema (DME) is an important cause of visual disability among patients with diabetes. It is widely recognized that cataract surgery often triggers severe CME in patients with pre-existing DME. This exacerbation begins immediately following cataract surgery; and unlike in non-diabetics the edema is likely to be protracted and poorly responsive both to traditional treatments for CME (topical NSAIDS) and DME (laser photocoagulation). Fluorescein angiography, a photographic test that evaluates the blood circulation in the back of the eye, has demonstrated that both CME and DME are associated with increased permeability of retinal blood vessels.

The high rates and severity of post-cataract surgery CME in diabetic patients with DME render this population ideal for the study of potential agents to reduce the rate and severity of this condition (i.e., post-cataract surgery CME). Recent studies have shown that vascular endothelial growth factor (VEGF) plays a major role in vessel permeability. Pegaptanib (Macugen) is an FDA-approved drug for wet AMD. Pegaptanib is a selective VEGF antagonist that blocks the effects of VEGF; therefore pegaptanib might decrease vessel permeability and possibly decrease the incidence and severity of CME. We plan to conduct a controlled pilot study to investigate the effects of pegaptanib (up to 3 treatments of pegaptanib given prior to cataract surgery and as often as every 6 weeks for up to 12 weeks after cataract surgery) in diabetic patients with pre-existing DME who are undergoing cataract surgery and who are, therefore, at very high risk for development of CME. Should the pilot study indicate a potential benefit of pegaptanib in this setting, a larger, fully powered clinical trial will be proposed. An effective treatment or preventive measure for post-cataract surgery macular edema in patients with diabetic retinopathy would offer benefit to a large patient population nationally that is at high risk of vision loss.

Conditions

Cystoid Macular Edema

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

A

Group Type: EXPERIMENTAL

Pegaptanib sodium

Intervention Type: DRUG

0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections

B

Group Type: PLACEBO_COMPARATOR

Control

Intervention Type: DRUG

Sham injection, every 6 weeks, up to a total of 3 sham injections

Interventions

Pegaptanib sodium

0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections

Intervention Type: DRUG

Control

Sham injection, every 6 weeks, up to a total of 3 sham injections

Intervention Type: DRUG

Other Intervention Names

Macugen

Eligibility Criteria

Inclusion Criteria

• Adults (ages 18 years or older) with diabetes mellitus
• Best corrected visual acuity worse than 20/40 but no worse than 20/800 in the study eye
• Best corrected visual acuity better than or equal to 20/800 in the fellow eye
• DME in the study eye (eye scheduled to undergo cataract surgery) as documented on OCT as a center point thickness of at least 250 microns no more than 3 weeks prior to cataract surgery
• No prior laser photocoagulation in the study eye for at least 4 months prior to cataract surgery
• Women of child-bearing potential who are interested in participating in this study will use two effective forms of contraception prior to initiation of pegaptanib and then throughout the remainder of the study. For women of childbearing potential, results from a urine pregnancy test will be obtained prior to each injection with pegaptanib. Urine samples will be disposed of after the test is performed.

Exclusion Criteria

• History of intravitreal steroid (triamcinolone) injection into the study eye within 4 months prior to cataract surgery
• Macular edema due to non-diabetic etiologies such as vein occlusion
• Retinal diseases that preclude evaluation of the macula for edema (e.g., macular hole)
• Media opacity will not be an exclusion criterion provided that the investigator can assess the presence or absence of DME on OCT

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eyetech Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Johns Hopkins University

Principal Investigators

Oliver D. Schein, MD, MPH, MBA

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

The Johns Hopkins Hospital

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

NA_00001385

Identifier Type: -

Identifier Source: org_study_id